Tamoxifen and Ftorafur for Breast Cancer Treatment
Author Information
Author(s): J. Uchino, N. Samejima, T. Tanabe, H. Hayasaka, M. Mito, Y. Hata, K. Asaishi
Primary Institution: Hokkaido University School of Medicine
Hypothesis
Does the combination of ftorafur and tamoxifen improve outcomes in breast cancer patients compared to ftorafur alone?
Conclusion
The study found that adding tamoxifen to ftorafur significantly improved survival and disease-free rates in breast cancer patients.
Supporting Evidence
- Patients receiving tamoxifen had a significantly higher 5-year survival rate compared to those who did not.
- The combination therapy showed no increase in side effects compared to ftorafur alone.
- Node-positive patients benefited more from tamoxifen than node-negative patients.
- Premenopausal women showed significantly better survival rates with tamoxifen.
Takeaway
This study shows that giving tamoxifen along with another drug called ftorafur helps breast cancer patients live longer and stay cancer-free after treatment.
Methodology
A prospective randomized multicenter clinical study comparing two treatment protocols over 5 years.
Potential Biases
Potential bias due to differences in treatment protocols across regions.
Limitations
Some patients were excluded due to ineligibility, and there were deviations from the protocol in different regions.
Participant Demographics
Female patients aged 75 or below with stage II or IIIa breast cancer who underwent radical mastectomy.
Statistical Information
P-Value
0.004
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website